CPMV Mosaic ImmunoEngineering Inc.
Distress ·
Mosaic ImmunoEngineering missed the 5:30 p.m. EDT August 14, 2025 deadline for its second-quarter report, citing financial reporting and close procedures. Its annual report warned it might have to cease operations if a deal with Oncotelic and note-holder waivers were not secured by June 30, 2025.
We have not published a story on Mosaic ImmunoEngineering yet. When there is news, it will appear here.
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. It has historically advanced early-stage product candidates and is pursuing new product candidates and platforms to build a pipeline. Its corporate history includes a license option and then a license from Case Western Reserve University for the cowpea mosaic virus (CPMV) platform technology, to treat and prevent cancer and infectious diseases. That license was terminated on March 22, 2024. In April 2024 the company entered a binding term sheet with Oncotelic Therapeutics, Inc. to acquire rights to clinical stage necroptosis cancer therapies associated with vascular disruptive agents, along with non-exclusive access to Oncotelic's artificial intelligence technologies for identifying immunotherapy combinations. That term sheet expired on June 30, 2025, and the text says discussions are ongoing to bring in a technology portfolio. The company says its funding has primarily come from the issuance of convertible notes.
| Product or program | What it is | Stage |
|---|---|---|
| CPMV platform | Cowpea mosaic virus platform for cancer and infectious diseases | license terminated March 22, 2024 |
| Oncotelic necroptosis cancer therapies | Proposed rights to clinical stage vascular disruptive agent therapies | binding term sheet expired June 30, 2025 |
Mosaic ImmunoEngineering Inc. trades under the ticker CPMV on OTC.
Mosaic ImmunoEngineering Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Mosaic ImmunoEngineering Inc. is 836564. Its filings are on SEC EDGAR.
7,242,137 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Mosaic ImmunoEngineering Inc. under United States.
Our directory classifies Mosaic ImmunoEngineering Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Mosaic ImmunoEngineering Inc. is US61945M1018.
aibio.space lists Mosaic ImmunoEngineering Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. It has historically advanced early-stage product candidates and is pursuing new product candidates and platforms to build a pipeline.
CPMV platform: Cowpea mosaic virus platform for cancer and infectious diseases Stage: license terminated March 22, 2024.
Oncotelic necroptosis cancer therapies: Proposed rights to clinical stage vascular disruptive agent therapies Stage: binding term sheet expired June 30, 2025.
Mosaic ImmunoEngineering Inc. reported a net loss of $687,846 for the fiscal year ended Dec 31, 2025, and used $111,397 of cash in operations, per its annual report to the SEC.
$63,981 in the fiscal year ended Dec 31, 2025, per its annual report.
$26 in cash at Jun 30, 2026, per its 10-Q.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio